Related Articles

News
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
September 7, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]

News
STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
January 10, 2023
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
Medicare Advantage providers Oak Street & Agilon Health chart out ambitious growth on day one of #JPM23. […]

News
STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
January 11, 2023
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. […]